Pulse Biosciences Hit 2-Year High on FDA Status for Surgery System
By Dean Seal
Shares of Pulse Biosciences hit a two-year high after regulators granted breakthrough device designation for Pulse's cardiac surgery system for the ablation of cardiac tissue during atrial fibrillation.
The stock rose 28% to a high of $15.43 in early trading. Shares haven't traded this high since January 2022.
Breakthrough device designation is granted to devices that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions for which no approved alternative exists.
The Miami-based company said Monday that the Food and Drug Administration's special designation would help it seek premarket approval for the system in the treatment of atrial fibrillation.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
July 08, 2024 11:19 ET (15:19 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks
United States